کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3328594 1212325 2015 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Aflibercept a new target therapy in cancer treatment: a review
ترجمه فارسی عنوان
افلایبرت یک هدف جدید درمان در درمان سرطان: بررسی
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی هماتولوژی
چکیده انگلیسی

Angiogenesis is the process through which new blood vessels are formed from pre-existing vessels and is essential for the growth of all solid tumors. Vascular endothelial growth factor (VEGF) is a regulator of angiogenesis, which is crucial for tumor growth and metastasis. Its inhibition with antiangiogenic drugs is thought to improve delivery of chemotherapy through vascular normalization and disruption of tumor vasculature. Aflibercept is a recombinant fusion protein of the VEGF receptor (VEGFR)1 and VEGFR2 extracellular domains that binds to VEGF-A, VEGF-B, placental growth factor (PlGF) 1 and 2. Aflibercept has demonstrated preclinical efficacy in different tumor types and exerts its antiangiogenic effects through regression of tumor vasculature, remolding of vasculature, and inhibition of new tumor vessel growth. This review examines the effects of aflibercept on tumor vasculature and on different types of solid tumors, and explores the preclinical and clinical benefits of inclusion aflibercept into anticancer treatment strategies.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Critical Reviews in Oncology/Hematology - Volume 96, Issue 3, December 2015, Pages 569–576
نویسندگان
, , ,